Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INaMICRON: Ranolazine for Prevention of Coronary Microvascular Dysfunction After STEMI
2025-520801-12-00Phase 2Authorised
- Sponsor
- University of Naples Federico II
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in myocardial infarction (MI) and Coronary Small Vessel Disease (CMD) comparing Ranolazine plus standard of care with Standard of care alone (2 arms). Primary endpoint: Relative change in index of microcirculatory resistance (IMR and/or angioIMR). Planned start Oct 2025; status: authorised.
02
Drugs
ranolazine
03
Conditions
myocardial infarction (MI)Coronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on 2025-520801-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520801-12-00.